Pre-conditioned mesenchymal stem cells: A better way for cell-based therapy

Stem Cell Research and Therapy

Volumn 4, Issue 3, 2013, Pages

  Li, Qing ^a   Wang, Yang ^a   Deng, Zhifeng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAUSE OF DEATH; CELL CULTURE; CELL THERAPY; HEART INFARCTION; HUMAN; IMMUNOREGULATION; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL; MICROENVIRONMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; ANIMAL; CYTOLOGY; MALE; MESENCHYMAL STROMA CELL; METABOLISM;

NOTCH1 RECEPTOR;

ANIMALS; MALE; MESENCHYMAL STROMAL CELLS; OXIDATIVE STRESS; RECEPTOR, NOTCH1;

EID: 84878666256     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt213     Document Type: Review

References (11)

1. Oxidative stress-induced Notch1 signaling promotes cardiogenic gene expression in mesenchymal stem cells. Boopathy AV, Pendergrass KD, Che PL, Yoon YS, Davis ME, Stem Cell Res Ther 2013 4 43 10.1186/scrt190 23597145
2. Transplantation of parthenogenetic embryonic stem cells ameliorates cardiac dysfunction and remodelling after myocardial infarction. Liu Y, Ye X, Mao L, Cheng Z, Yao X, Jia X, Mao D, Ou L, Li Z, Che Y, Liu N, Steinhoff G, Liu L, Kong D, Cardiovasc Res 2013 97 208 218 10.1093/cvr/cvs314 23066088
3. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, Morales AR, Da Silva J, Sussman MA, Heldman AW, Hare JM, Circulation 2013 127 213 223 10.1161/CIRCULATIONAHA.112.131110 23224061
4. Mesenchymal stem cell therapy for heart disease. Gnecchi M, Danieli P, Cervio E, Vascul Pharmacol 2012 57 48 55 10.1016/j.vph.2012.04.002 22521741
5. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y, Shi Y, Stem Cells Transl Med 2011 1 51 58 23197640
6. Acute preconditioning of cardiac progenitor cells with hydrogen peroxide enhances angiogenic pathways following ischemia-reperfusion injury. Pendergrass K, Boopathy A, Seshadri G, Maiellaro-Rafferty K, Che PL, Brown M, Davis ME, Stem Cells Dev 2013 [Epub ahead of print]
7. Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex. Song H, Cha MJ, Song BW, Kim IK, Chang W, Lim S, Choi EJ, Ham O, Lee SY, Chung N, Jang Y, Hwang KC, Stem Cells 2010 28 555 563 20073042
8. Pharmacologically active microcarriers influence VEGF-A effects on mesenchymal stem cell survival. Penna C, Perrelli MG, Karam JP, Angotti C, Muscari C, Montero-Menei CN, Pagliaro P, J Cell Mol Med 2013 17 192 204 10.1111/j.1582-4934.2012.01662.x 23305078
9. Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Herrmann JL, Wang Y, Abarbanell AM, Weil BR, Tan J, Meldrum DR, Shock 2010 33 24 30 10.1097/SHK.0b013e3181b7d137 19996917
10. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A, J Am Coll Cardiol 2010 56 721 734 10.1016/j.jacc.2010.03.066 20723802
11. Cardiopoietic stem cell therapy in heart failure: The C-CURE multicenter randomized trial with lineage-specified biologics. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, Nakadi BE, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A, J Am Coll Cardiol 2013 10.1016/j.jacc.2013.02.071